Xeris files KEVEYIS suits. Barclays lifts target for Xeris Biopharma Holdings stock

Published on 10/18/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 92.10 million on June 30, 2026. Xeris Biopharma Holdings stock is valued at USD 1.9 billion as of October 16, 2026.

Catalysts and financial markers

Xeris filed two KEVEYIS patent lawsuits on October 13, 2026, citing U.S. Patent No. 12,758,502.
Second-quarter revenue reached USD 92.10 million for the period ended June 30, 2026, while net loss was USD 31.10 million.
Barclays raised its Xeris target from USD 12.00 to USD 14.00 on October 6, 2026.

XERS, US98422E1038, Illustration mit AI erstellt.

Xeris Biopharma Holdings (ISIN US98422E1038) filed two KEVEYIS patent infringement lawsuits on October 13, 2026, after receiving U.S. Patent No. 12,758,502. The move adds an intellectual-property defense to a portfolio story shaped by commercial growth, upcoming clinical data and analyst target increases.

Patent action adds product defense

According to the SEC filing dated October 13, 2026, Xeris Pharmaceuticals filed the cases in the United States District Court for the District of New Jersey against Torrent Pharma, Cycle Pharmaceuticals, Lemed Pharmacy and Rising Pharma affiliates. The complaints allege infringement involving generic dichlorphenamide products and seek injunctions, damages and legal costs.

What does the portfolio show?

The latest reported quarter ended June 30, 2026, with revenue of USD 92.10 million and a net loss of USD 31.10 million, according to Yahoo Finance. Revenue exceeded the cited USD 90.12 million consensus estimate by USD 1.98 million, but adjusted expectations were not met because reported loss per share was USD 0.18 against a projected USD 0.01 profit.

The chronology is clear: Xeris reported second-quarter revenue of USD 92.10 million on August 6, 2026; it granted equity awards covering 352,170 shares to 60 new employees on October 1, 2026, according to Business Wire; and it filed the two KEVEYIS cases on October 13, 2026.

Analysts raise the valuation bar

Barclays raised its Xeris price target from USD 12.00 to USD 14.00 on October 6, 2026, while keeping an Overweight rating, as reported by Markets Insider. The target change puts greater emphasis on whether Recorlev growth, Gvoke adoption and the XP-8121 pipeline can support the commercial valuation.

Two dates shape the next test

Xeris is scheduled to present hypothyroidism data at the American Thyroid Association Annual Meeting on November 6, 2026, according to the Xeris Biopharma release. A separate market calendar lists November 5, 2026 as the next quarterly reporting date, giving investors two closely timed events for assessing execution.

Market value and trading dates

Xeris had a USD 1.9 billion market capitalization and a USD 5.25 to USD 11.33 52-week range as of October 16, 2026. Its Nasdaq Global Select Market listing places the patent dispute, quarterly figures and upcoming data presentation in the same valuation frame.

The further course of trading is shown by the continuously updated real-time quote of Xeris Biopharma Holdings stock.